Durvalumab
D419CC00002
Phase 3 small_molecule active
Quick answer
Durvalumab for Hepatocellular Carcinoma is a Phase 3 program (small_molecule) at AstraZeneca with 2 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- Hepatocellular Carcinoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active